Approval · Notice of Compliance 15966 · 2014
ABRAXANE: Notice of Compliance 15966
Issued July 16, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 15966
- Date
- July 16, 2014
- Company
- Celgene IncSaint-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: the first-line treatment of locally advanced unresectable or metastatic adenocarcinoma of the pancreas, in combination with gemcitabine
- Therapeutic class
- Antineoplastic agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ABRAXANE | Not yet assigned | — |
Medicinal ingredients
- PACLITAXEL 100 MG per VIAL